fda compounding semaglutide warning 2025 october Patient Safety Updates FDA issued 25 warning letters

However, those benefits come at a significant financial cost, with annual treatment expenses typically ranging from $12,000 to $16,000 per patient. GLP1 coverage is one of the most consequential benefit decisions employers will face in 2026

The most common include nausea, constipation, and fatigue

Im probably not the best person to answer this, but not only am I the spokesperson, but Im also one of the members

Thus, SGLT2is and GLP1-RAs may have different mechanisms in microvascular and macrovascular complications of T2DM

Semaglutide is a medication that mimics the effect of GLP-1, a hormone produced in your gut after you eat, and it has several effects on your body, such as: Stimulating insulin secretion and lowering blood sugar levels Slowing down gastric emptying and reducing food intake Increasing energy expenditure and fat-burning Reducing appetite and hunger Enhancing satiety and fullness Semaglutide was originally approved by the FDA as a treatment for type 2 diabetes, and in 2021, it was approved for chronic weight management in adults